Summary
Lipids
Glucose
Metabolic
Thyroid
Immune
Hormones
Omega & fats
GI Map
Correlations
Genotype
⚠ Action Items
Show:
Most recent value per marker. Generated dynamically from database.
Key ongoing concerns
Autoimmune activity
ANA 1:1280 + anti-centromere positive + elevated TPO/TgAb. Pattern consistent with limited systemic sclerosis (CREST) or undifferentiated CTD. ANA elevated since at least February 2006.
Lipids
LDL persistently elevated. ApoB borderline. Improved dramatically with Zepbound (138 Oct 2024 to 89 Mar 2025). TG consistently excellent (45-88 mg/dL).
GI / Microbiome
H. pylori trending up 106% with iceA virulence factor (clarithromycin-resistant). Calprotectin 192 (new finding, ref <173). Candida 11x above ref. Akkermansia absent both tests. Treatment decision needed
Thyroid
TSH normalized 8.77 → 3.01 with NP Thyroid titration. TPO/TgAb trending down. Free T4 stable.
Hormones
DHEA-S now in range at 139 mcg/dL (Feb 2026) after overshoot to 426 (Jun 2025). Testosterone normalized to 27 ng/dL. 35 mg/day DHEA dose since Mar 2026.
Omega / inflammatory fats
Omega-3 Index 10%, Omega-6:Omega-3 3.8:1, Trans Fat Index 0.51% -- all desirable. AA:EPA 7.6:1 upper half. Monitor AA:EPA -- target <5:1 on next draw
Lipid panel over time
All values mg/dL. Mar 2025 = Zepbound nadir draw (LDL + ApoB only). Dashed blue = LDL goal 100.
Cholesterol/HDL Ratio
Friedewald equation. Ideal <3.5 (dashed blue). First captured 6/19/2026.
Glucose markers over time
Left axis: HbA1c %. Right axes: fasting glucose mg/dL (purple) and fasting insulin uIU/mL (pink). Jun 2025 insulin only.
Additional insulin resistance markers
LP-IR Score (Jan 2025)
27 -- insulin sensitive (<45 = normal)
GlycoMark 1,5-AG (Jan 2025)
12.0 ug/mL -- normal glycemic control
Comprehensive Metabolic Panel markers not covered by Glucose/Lipids. First captured numerically 6/19/2026 (Clin Labs of Hawaii).
% of clinical target reached
Globulin: % of its 2.0-3.6 g/dL reference band (0% = at/below floor). eGFR: value as % of the >=90 mL/min/1.73m2 normal threshold.
Thyroid markers over time
Left: TSH mIU/L (green). Right: antibodies IU/mL (pink/purple) and Free T4 ng/dL (orange). Red/yellow dots = out of range TSH.
ANA / autoimmune panel -- persistent findings
ANA titer history
Elevated since at least Feb 2006 (20+ years). Most recent: 1:1280 (Sep 2024, Mar 2025). Pattern: discrete speckled & centromere.
Anti-centromere IgG Ab
>8.0 AI (Mar 2025) -- Positive (ref <1.0). Specific for limited scleroderma / CREST.
Anti-dsDNA (Mar 2025)
<10 titer -- Negative. Rules out lupus (SLE) as primary driver.
RF (Mar 2025)
<10 IU/mL -- Negative.
TPO Ab
56 (Sep 2024) to 35 (Oct 2024) to 28 (Jan 2025) -- trending down
TgAb
141 (Sep 2024) to 90 (Mar 2025) -- trending down
CRP-hs trend
ref <1.0 mg/L (low risk). 1-3 = average. >3 = high. Jun 2025 spike = DHEA overshoot, not autoimmune flare.
Eosinophils %
ref 0-6%. Rechecked 6/19/2026: 1.2% -- normal, resolved. Prior concern was 8.0% (Mar 2025) + H. pylori iceA positive (Mar 2026).
Candida Antibody (IgA / IgG / IgM)
ref <=0.88 EV each (dashed red). First captured 6/19/2026: IgA + IgG positive, IgM negative -- corroborates GI-MAP Candida ~11x reference finding.
DHEA-S, testosterone & vitamin D
Left: DHEA-S mcg/dL (purple). Right: Testosterone ng/dL (red) + Vitamin D ng/mL (orange). Dashed = upper refs.
Estradiol, FSH, LH, progesterone & IGF-1
Left: Estradiol pg/mL + IGF-1 ng/mL. Right: FSH + LH mIU/mL + Progesterone x100 ng/mL.
OmegaQuant Analytics - Collection 2026-03-31 - Result 2026-04-17 - First test, baseline established
Omega markers -- % position within desirable range (--)
100% = at the upper bound of the desirable range.
Clinical interpretation
Omega-3 Index 10%
Solidly in the desirable 8-12% range. Associated with reduced cardiovascular and inflammatory risk. In desirable range
Omega-6:Omega-3 3.8:1
Excellent -- near the lower (optimal) end of the 3:1-5:1 target. US population average ~10-15:1. In desirable range
AA:EPA 7.6:1
Within range but upper half. Most effective lever: EPA-specific supplementation. Retest ~July 2026. Target <5:1 on next draw
Trans Fat Index 0.51%
Well below the <1% target. No dietary intervention needed. In desirable range
Diagnostic Solutions GI-MAP qPCR | -- | Ordered by Dr. John R. Anderson, DC
⚠ H. pylori status
Oct 2024
3.51e2 GE/g -- below ref (<1.0e3). No virulence factor testing ordered.
Mar 2026
7.21e2 GE/g -- still below ref but +106%. iceA virulence factor: POSITIVE (enhanced mucosal IL-8, peptic ulcer risk).
Clarithromycin
RESISTANT (A2142C mutation) -- Standard triple therapy CONTRAINDICATED. Use bismuth quadruple or amoxicillin + metronidazole + PPI.
Amoxicillin / Fluoroquinolones / Tetracycline
Sensitive
Intestinal health markers -- % of upper reference limit
Values normalized to their upper reference limit. 100% = at threshold. Red = above ref (HIGH). Secretory IgA shown as % of lower bound (510 µg/g).
Calprotectin & Zonulin trend
Left: Calprotectin µg/g (ref <173, dashed red). Right: Zonulin ng/g (ref <175, dashed orange).
Key organisms: -- (log10 scale)
Logarithmic scale. Each unit = 10x difference. Gray dashed = upper reference limit where applicable.
Organism comparison table
Cross-marker relationships from time-matched lab data Oct 2024 -- Mar 2026. Directional only.
DHEA-S vs CRP-hs -- dosing-driven co-movement
As DHEA supplementation was titrated up then corrected, CRP tracked with it. Jun 2025 spike = DHEA overshoot.
Actionable
Always order CRP and DHEA-S in the same draw. Do not interpret a future CRP rise as autoimmune flare without simultaneously checking DHEA-S.
DHEA-S vs Testosterone -- strong directional relationship
Actionable
If testosterone exceeds 45 ng/dL on next draw, DHEA dose likely needs reduction.
Metabolic markers -- parallel improvement (normalized to first draw)
LDL, HbA1c, and CRP all improved in parallel with Zepbound + lifestyle changes.
Clinically relevant variants from Promethease report. Interpreted in context of actual lab findings 2024-2026.
COMT -- rs4680 (AA homozygous) - Slow estrogen clearance
What it means
COMT encodes catechol-O-methyltransferase, which methylates and inactivates catechol estrogens. The AA genotype has ~3-4x lower enzyme activity.
DUTCH test finding
Methylation ratio 0.30 -- confirmed below range. Slow COMT activity validated by functional testing.
Actionable
Maintain adequate methyl donors (B12, folate, B6, choline). Estradiol 218 pg/mL (Feb 2026) -- recheck DUTCH if starting HRT
APOA5 -- rs662799 (T;T) - Protective triglyceride regulation
Lab confirmation
TG consistently excellent: 90 to 88 to 85 to 45 mg/dL (Feb 2026). Genotype advantage clearly expressed.
Actionable
TG is not a primary concern. No dietary TG intervention needed
SLC30A8 -- Zinc transporter - Insulin secretion risk
Lab history
HbA1c peaked 5.9% (Oct 2024) -- reversed to 5.3% (Feb 2026) with Zepbound + visceral fat reduction.
Actionable
Maintain HbA1c <5.7%. Do not let visceral fat rebound. Currently normalized Monitor if Zepbound is discontinued
PNPLA3 -- Liver fat / NAFLD susceptibility
Current status
ALT 14 U/L (Feb 2026), AST 15 -- well within range. Visceral fat 16 to 8 (normal). No current NAFLD signal.
Actionable
Watch ALT >30 U/L as early signal. Recheck with each lab draw. ALT 14 -- well controlled
MTHFR -- Methylation / homocysteine context
Lab finding
Homocysteine 6.0-6.6 umol/L across all draws -- well below the <13.4 upper limit. Methylation pathway functionally adequate.
Actionable
No homocysteine intervention needed. Continue B12 and folate maintenance. Homocysteine 6.0 -- optimal
Autoimmune genetic context
ANA / anti-centromere
No specific HLA or CENP gene variants identified in Promethease as primary driver. The autoimmune finding is clinical, not solely genetic.
Actionable
Rheumatology referral if symptoms of scleroderma (Raynaud's, dysphagia, skin thickening) develop or worsen. No rheumatology follow-up documented
Prioritized action items across all health categories. Items flagged from GI-MAP (Apr 2026 analysis), blood labs, and ongoing monitoring.
⚠ Immediate -- discuss at next appointment
1H. pylori treatment decision URGENT
Trending up +106% (3.51e2 → 7.21e2), iceA virulence factor now positive, clarithromycin-resistant (A2142C). Options: (a) treat proactively now or (b) wait until it crosses 1.0e3 threshold on next GI-MAP. If treating: clarithromycin-free protocol required -- bismuth quadruple therapy or amoxicillin + metronidazole + PPI. DO NOT use standard triple therapy. Discuss with Dr. Anderson or GI physician.
2Calprotectin 192 -- retest in 3 months NEW FINDING
Fecal calprotectin 5 (Oct 2024) → 192 HIGH (Mar 2026, ref <173). In anti-centromere positive / scleroderma-pattern patient, calprotectin elevation may reflect autoimmune GI involvement (mucosal vasculopathy) independent of dysbiosis. Retest with next GI-MAP in ~3 months. If >200: GI physician referral to rule out scleroderma GI involvement vs. infectious/dysbiotic cause.
3Eosinophils -- recheck on next CBC RESOLVED
Rechecked 6/19/2026 (Clin Labs of Hawaii): 1.2% (ref 0-6%) -- normal, well below the 8% watch threshold. Prior elevation (8.0%, Mar 2025) plus H. pylori iceA positivity (Mar 2026) prompted the recheck; no eosinophilic process indicated at this draw.
4Candida albicans -- confirm treatment plan
Total Candida dropped 97% (1.69e6 → 5.48e4) but remains 11x above reference. Candida albicans is newly detectable and elevated (1.11e3, ref <500). Possible species shift as non-albicans Candida was treated. C. albicans produces more biofilm and is more virulent. Confirm with Dr. Anderson whether antifungal protocol needs adjustment for albicans-specific treatment.
5Streptococcus spp. -- unchanged x2 tests
4.28e3 (Oct 2024) → 4.33e3 (Mar 2026). Reference <1.0e3. Persistent elevation unchanged despite treating other overgrowths. Ask Dr. Anderson what protocol has been applied; may need targeted intervention.
Self-directed (discuss with Dr. Anderson before implementing)
6Akkermansia muciniphila -- targeted dietary intervention
Absent on both Oct 2024 and Mar 2026 tests. Akkermansia colonizes the mucus layer and its absence impairs intestinal barrier integrity. Primary substrates: dietary polyphenols (pomegranate, cranberry, green tea) and fermentable fiber (inulin, FOS). Pendulum probiotic contains live Akkermansia -- discuss with Dr. Anderson before adding. Monitor: look for first appearance on next GI-MAP as marker of intervention success.
7Butyrate producers -- resistant starch protocol
Roseburia spp. still low (1.12e7, ref 5.0e7-2.0e10). F. prausnitzii newly detectable but still low (1.87e4, ref 1.0e3-5.0e8). These obligate anaerobes cannot be supplemented via standard probiotics. Feed them in situ: increase resistant starch (cooled cooked potato, green banana flour, oats) and psyllium husk. Possible mechanism: persistent butyrate deficiency → declining HRV (20.2 → 15.7 ms) via gut-brain axis.
Monitor at next GI-MAP / blood draw
8DHEA-S / Testosterone -- watch dose stability
DHEA-S currently 139 mcg/dL (Feb 2026, ref <167). Testosterone 27 ng/dL (ref <45). Watch: if testosterone >45 ng/dL on next draw at 35 mg/day dose, reduce DHEA. Always order CRP and DHEA-S in the same draw -- do not interpret a CRP rise without simultaneously checking DHEA-S (DHEA overshoot drives CRP artificially high).
9Anti-gliadin IgA -- trending up (still normal)
Anti-gliadin IgA: 15 (Oct 2024) → 55 (Mar 2026). Reference <175. Not diagnostic, but 3.7x increase is notable. Monitor: if approaches 100, discuss gluten elimination trial with Dr. Anderson to assess whether this is driving intestinal immune reactivity.
10AA:EPA ratio retest ~July 2026
AA:EPA 7.6:1 (Mar 2026, desirable <5:1). EPA-specific supplementation started Apr 2026. Order OmegaQuant retest ~July 2026 (3-4 months post-supplementation). Expect AA:EPA to shift; also check Omega-3 Index stability.